We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, is well poised for growth in the coming quarters, backed by its slew of strategic deals over the past few months. A robust fourth-quarter fiscal 2021 performance, along with several regulatory approvals, is expected to contribute further. Significant consolidation and a stiff competitive landscape persist.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 4.3% compared with 11.9% growth of the industry and 25.7% rise of the S&P 500.
The renowned medical technology company has a market capitalization of $71.11 billion. The company projects 7.3% growth for the next five years and expects to maintain its strong performance. BD has delivered an earnings surprise of 16.95% for the past four quarters, on average.
Image Source: Zacks Investment Research
Let’s delve deeper.
Regulatory Approvals: We are optimistic about BD’s impressive progress on the regulatory front with respect to its products. The company, in October, received the FDA’s 510(k) clearance for expanded indications for the Rotarex Atherectomy System.
BD, in August, announced receipt of the FDA’s Emergency Use Authorization for the BD Veritor At-Home COVID-19 Test. The test is an over-the-counter rapid antigen test that utilizes the Scanwell Health mobile app to deliver reliable results in 15 minutes.
Strategic Deals: We are upbeat about BD’s slew of strategic deals over the past few months. The company, this month, acquired Venclose, Inc., which is expected to enable it to offer a more robust portfolio of solutions to physicians treating the full range of venous conditions.
BD, in October, announced the formation of a public-private partnership with the Biomedical Advanced Research and Development Authority (part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response) to support the development of a range of COVID-19 combination diagnostic tests for core laboratories, hospitals and at the point of care.
Strong Q4 Results: BD’s solid fourth-quarter fiscal 2021 results buoy our optimism. The company recorded robust segmental performances, along with solid geographical revenues, which are impressive. The launches of BD’s FACSymphony A1 Cell Analyzer and COR System are encouraging.
Downsides
Stiff Competition: BD faces significant competition from a wide range of companies. These include large medical device companies with multiple product lines, some of which may have greater financial and marketing resources, as well as firms that are more specialized than BD is with respect to particular markets or product lines. The company faces competition across all its product lines and in markets in which its products are sold.
Significant Consolidation: The medical technology industry has experienced considerable consolidation, resulting in companies with greater scale and market presence than BD. Traditional distributors are also manufacturers of medical devices, providing another source of competition.
Estimate Trend
BD is witnessing a positive estimate revision trend for 2021. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 0.6% north to $12.41.
The Zacks Consensus Estimate for the company’s first-quarter fiscal 2022 revenues is pegged at $4.76 billion, suggesting a 10.4% fall from the year-ago quarter’s reported number.
Key Picks
A few other better-ranked stocks in the broader medical space are Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp, Thermo Fisher Scientific Inc. (TMO - Free Report) and AMN Healthcare Services (AMN - Free Report) .
LabCorp, carrying a Zacks Rank #2 (Buy), reported third-quarter 2021 adjusted EPS of $6.82, which beat the Zacks Consensus Estimate by 42.9%. Revenues of $4.06 billion outpaced the consensus mark by 13.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
LabCorp has an estimated long-term growth rate of 10.6%. The company surpassed estimates in the trailing four quarters, the average surprise being 25.73%.
Thermo Fisher reported third-quarter 2021 adjusted EPS of $5.76, which surpassed the Zacks Consensus Estimate by 23.3%. Third-quarter revenues of $9.33 billion outpaced the Zacks Consensus Estimate by 12%. It currently carries a Zacks Rank #2.
Thermo Fisher has an estimated long-term growth rate of 14%. The company surpassed estimates in the trailing four quarters, the average surprise being 9.02%.
AMN Healthcare reported third-quarter 2021 adjusted EPS of $1.73, which surpassed the Zacks Consensus Estimate by 29.1%. Third-quarter revenues of $877.8 million outpaced the Zacks Consensus Estimate by 12.3%. It currently sports a Zacks Rank #1.
AMN Healthcare has an estimated long-term growth rate of 16.2%. The company surpassed estimates in the trailing four quarters, the average surprise being 19.51%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, is well poised for growth in the coming quarters, backed by its slew of strategic deals over the past few months. A robust fourth-quarter fiscal 2021 performance, along with several regulatory approvals, is expected to contribute further. Significant consolidation and a stiff competitive landscape persist.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 4.3% compared with 11.9% growth of the industry and 25.7% rise of the S&P 500.
The renowned medical technology company has a market capitalization of $71.11 billion. The company projects 7.3% growth for the next five years and expects to maintain its strong performance. BD has delivered an earnings surprise of 16.95% for the past four quarters, on average.
Let’s delve deeper.
Regulatory Approvals: We are optimistic about BD’s impressive progress on the regulatory front with respect to its products. The company, in October, received the FDA’s 510(k) clearance for expanded indications for the Rotarex Atherectomy System.
BD, in August, announced receipt of the FDA’s Emergency Use Authorization for the BD Veritor At-Home COVID-19 Test. The test is an over-the-counter rapid antigen test that utilizes the Scanwell Health mobile app to deliver reliable results in 15 minutes.
Strategic Deals: We are upbeat about BD’s slew of strategic deals over the past few months. The company, this month, acquired Venclose, Inc., which is expected to enable it to offer a more robust portfolio of solutions to physicians treating the full range of venous conditions.
BD, in October, announced the formation of a public-private partnership with the Biomedical Advanced Research and Development Authority (part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response) to support the development of a range of COVID-19 combination diagnostic tests for core laboratories, hospitals and at the point of care.
Strong Q4 Results: BD’s solid fourth-quarter fiscal 2021 results buoy our optimism. The company recorded robust segmental performances, along with solid geographical revenues, which are impressive. The launches of BD’s FACSymphony A1 Cell Analyzer and COR System are encouraging.
Downsides
Stiff Competition: BD faces significant competition from a wide range of companies. These include large medical device companies with multiple product lines, some of which may have greater financial and marketing resources, as well as firms that are more specialized than BD is with respect to particular markets or product lines. The company faces competition across all its product lines and in markets in which its products are sold.
Significant Consolidation: The medical technology industry has experienced considerable consolidation, resulting in companies with greater scale and market presence than BD. Traditional distributors are also manufacturers of medical devices, providing another source of competition.
Estimate Trend
BD is witnessing a positive estimate revision trend for 2021. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 0.6% north to $12.41.
The Zacks Consensus Estimate for the company’s first-quarter fiscal 2022 revenues is pegged at $4.76 billion, suggesting a 10.4% fall from the year-ago quarter’s reported number.
Key Picks
A few other better-ranked stocks in the broader medical space are Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp, Thermo Fisher Scientific Inc. (TMO - Free Report) and AMN Healthcare Services (AMN - Free Report) .
LabCorp, carrying a Zacks Rank #2 (Buy), reported third-quarter 2021 adjusted EPS of $6.82, which beat the Zacks Consensus Estimate by 42.9%. Revenues of $4.06 billion outpaced the consensus mark by 13.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
LabCorp has an estimated long-term growth rate of 10.6%. The company surpassed estimates in the trailing four quarters, the average surprise being 25.73%.
Thermo Fisher reported third-quarter 2021 adjusted EPS of $5.76, which surpassed the Zacks Consensus Estimate by 23.3%. Third-quarter revenues of $9.33 billion outpaced the Zacks Consensus Estimate by 12%. It currently carries a Zacks Rank #2.
Thermo Fisher has an estimated long-term growth rate of 14%. The company surpassed estimates in the trailing four quarters, the average surprise being 9.02%.
AMN Healthcare reported third-quarter 2021 adjusted EPS of $1.73, which surpassed the Zacks Consensus Estimate by 29.1%. Third-quarter revenues of $877.8 million outpaced the Zacks Consensus Estimate by 12.3%. It currently sports a Zacks Rank #1.
AMN Healthcare has an estimated long-term growth rate of 16.2%. The company surpassed estimates in the trailing four quarters, the average surprise being 19.51%.